Evidence map›Paper›PMID 27563821›Full record

ArticleOncotarget2016

AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma.

Giuseppina Conteduca, Daniela Fenoglio, Alessia Parodi, Florinda Battaglia, Francesca Kalli, Simone Negrini, Samuele Tardito, Francesca Ferrera, Annalisa Salis, Enrico Millo and 6 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Giuseppina ConteducaCentre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
Daniela FenoglioCentre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
Alessia ParodiCentre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
Florinda BattagliaCentre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
Francesca KalliCentre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
Simone NegriniCentre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
Samuele TarditoCentre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
Francesca FerreraCentre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
Annalisa SalisCentre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
Enrico MilloCentre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
Giuseppe PasqualeDepartment of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy.
Giusi BarraDepartment of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy.
Gianluca DamonteCentre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
Francesco IndiveriCentre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
Soldano FerroneDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Gilberto FilaciCentre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
University of Genoa · ITUniversity of Campania "Luigi Vanvitelli" · ITHarvard University · USOspedale Policlinico San Martino · IT

Funding

Combinatorial targeting of melanoma initiating cellsR01CA138188 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FERRONE, SOLDANO · 2008 to 2012
$1.5M
Antigen processing and HLA-peptide complexes in head and neck cancerR01CA110249 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FERRONE, SOLDANO · 2006 to 2010
$1.5M
NCI NIH HHS R01 CA110249NCI NIH HHS R01 CA138188
6 · The paper itself

Abstract

AIRE is involved in susceptibility to melanoma perhaps regulating T cell immunity against melanoma antigens (MA). To address this issue, AIRE and MAGEB2 expressions were measured by real time PCR in medullary thymic epithelial cells (mTECs) from two strains of C57BL/6 mice bearing either T or C allelic variant of the rs1800522 AIRE SNP. Moreover, the extent of apoptosis induced by mTECs in MAGEB2-specific T cells and the susceptibility to in vivo melanoma B16F10 cell challenge were compared in the two mouse strains.The C allelic variant, protective in humans against melanoma, induced lower AIRE and MAGEB2 expression in C57BL/6 mouse mTECs than the T allele. Moreover, mTECs expressing the C allelic variant induced lower extent of apoptosis in MAGEB2-specific syngeneic T cells than mTECs bearing the T allelic variant (p < 0.05). Vaccination against MAGEB2 induced higher frequency of MAGEB2-specific CTL and exerted higher protective effect against melanoma development in mice bearing the CC AIRE genotype than in those bearing the TT one (p < 0.05). These findings show that allelic variants of one AIRE SNP may differentially shape the MA-specific T cell repertoire potentially influencing susceptibility to melanoma.

Indexed as

AIRE ProteinAnimalsAntigens, NeoplasmApoptosisBone Marrow CellsCD8-Positive T-LymphocytesCpG IslandsDNA MethylationEpigenesis, GeneticEpithelial CellsFemaleGene Expression Regulation, NeoplasticGene SilencingGenetic Predisposition to DiseaseHumansMelanomaAIRE ProteinAntigens, NeoplasmMAGEB2 protein, humanMageb2 protein, mouseMelanoma-Specific AntigensNeoplasm ProteinsTranscription FactorsAIREImmune responseImmunityImmunology and Microbiology SectionMAGEmedullary thymic epithelial cellssingle nucleotide polymorphismtolerance

Identifiers

PMID27563821
PMCPMC5308622
OpenAlexW2305983567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.